GleamWall
中文EN

TTRX Turn Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2023016 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-236.5%
TTM EPS YoY-186.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-412.3%
ROA-123.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets65.2%
Debt / equity1.09x
Current ratio3.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-72.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$605,197$475,064$109,434$34,934$158,699$62,678$9,259$9,766
SG&A expense$1.38M$1.15M$1.14M$2.16M$1.75M$1.30M$375,738$319,191
Operating income-$1.98M-$1.63M-$1.25M-$2.19M-$1.91M-$1.37M-$384,997-$328,957
Interest expense$341,208———————
Net income-$6.23M-$5.85M-$970,972$279,070-$1.90M-$1.24M-$328,547-$323,130
EPS (basic)-0.21-0.20-0.03—-0.07-0.05-0.01—
EPS (diluted)-0.21-0.20-0.03—-0.07-0.05-0.01—
Weighted avg. shares (diluted)30.14M29.79M29.48M—27.98M27.49M26.96M—
Balance sheet
Cash & equivalents$9.43M$9.95M$11.01M$4.03M$3.11M$3.19M$1.57M$872,599
Current assets$11.08M$10.43M$11.45M$5.20M$3.29M——$1.10M
Intangibles$912,673$911,219$919,947$922,171$904,885——$821,931
Total assets$16.35M$16.96M$18.64M$12.16M$4.30M——$2.05M
Current liabilities$3.48M$8.76M$5.13M$6.00M$2.31M——$707,932
Short-term debt$444,204———————
Long-term debt$5.74M$6.06M$5.94M—————
Total debt$6.19M$6.06M$5.94M—————
Total liabilities$10.66M$16.27M$12.53M$7.48M$3.79M——$2.23M
Shareholders' equity$5.69M$686,888$6.12M$4.69M$504,013$1.77M$818,710-$177,432
Net debt-$3.25M-$3.89M-$5.07M—————
Shares outstanding30.53M29.79M29.79M29.45M28.02M——26.85M
Cash flow statement
Operating cash flow-$1.55M-$923,364-$1.63M-$1.18M-$588,610-$499,966-$298,058-$430,545
Investing cash flow-$16,140-$5,798-$12,227-$31,441-$89,794——-$7,842
Financing cash flow$1.64M$1$7.79M$3.18M$594,617$2.15M$998,092$522,206
Stock-based compensation$713,205$419,233$280,830$256,380$39,084$47,184$76,597$37,813

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.